Tag: innovate biopharmaceuticals

August 13, 2019

Innovate Biopharmaceuticals Doses First Patient in Phase 3 Clinical Trial CeD LA3001

Innovate Biopharmaceuticals (NASDAQ:INNT) has announced it has dosed the first patient in its Phase 3 clinical trial, CeD LA 3001....
March 18, 2019

Innovate Biopharmaceuticals Announces Entry Into Securities Purchase Agreement to Fund Initiation of the First Phase 3 Celiac Disease Clinical Trial

Innovate Biopharmaceuticals (NASDAQ:INNT) has announced it has entered into an agreement with SDS Capital Partners II LLC providing for the...
December 17, 2018

Innovate Biopharmaceuticals Plans to Commence the First Ever Phase 3 Registration Trial in Celiac Disease

Innovate Biopharmaceuticals (Nasdaq:INNT), a clinical stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases, is evaluating...
December 16, 2018

5 Top Weekly NASDAQ Biotech Stocks: Innovate Leads the Pack

Innovate Biopharmaceuticals, Aridis Pharmaceuticals, Imprimis Pharmaceuticals, Achaogen and SynthoRx were last week's top gainers.
October 29, 2018

Innovate Biopharmaceuticals Announces Positive Effect of Larazotide Acetate on reducing Intestinal Permeability

Innovate Biopharmaceuticals (Nasdaq:INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, announced today a...
July 31, 2018

Innovate Biopharmaceuticals Enters into a Collaboration on Larazotide’s Effect on Improving the Microbiome of Children with EED with the University of Virginia School of Medicine

Innovate Biopharmaceuticals (NASDAQ:INNT) has announced a collaboration with James P. Nataro, MD, PHD, MBDA, the Benjamin Armistead Shepherd Professor and...